HRMY,Harmony Biosciences Holdings, Inc. | Healthcare

Healthcare

HRMY

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

Harmony Biosciences Holdings, Inc.HRMY

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

Market Cap

1.64B

Revenue (ttm)

714.73M

Net Income (ttm)

145.49M

Shares Out

57.35M

EPS (ttm)

2.51

PE Ratio

11.07

Forward PE

8.84

Dividend

n/a

Ex-Dividend Date

n/a

Volume

174,667

Open

29.16

Previous Close

28.99

Day's Range

27.63 - 29.38

52-Week Range

26.47 - 41.61

Beta

0.80

Analysts

Strong Buy

Price Target

54.00 (+88.81%)

Earnings Date

Apr 29, 2025

Description >

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.

It offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020.

Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Latest News >

China's purchases of chipmaking equipment to decline in 2025, consultancy says

Feb 11, 2025

BEIJING/SHANGHAI, Feb 12 (Reuters) - China's purchases of chipmaking equipment are set to decline this year after three years of growth, as the industry grapples with overcapacity and faces greater constraints from U.S. sanctions, a consultancy said on Wednesday. China has been the biggest buyer of wafer fabrication equipment for at least the past two years, purchasing $41 billion worth...

SoftBank books surprise loss of $2.4 billion in third quarter

Feb 11, 2025

TOKYO, Feb 12 (Reuters) - Japanese technology investor SoftBank Group booked a surprising net loss of 369.2 billion yen ($2.4 billion) in the October-December quarter as valuations at its Vision Fund investment arm fell. In particular, SoftBank was hit by unrealised valuation losses for South Korean e-commerce platform Coupang ( CPNG ), Chinese ride-hailing firm Didi Global and AutoStore Holdings...

Supermarket group Ahold Delhaize's fourth-quarter sales marginally beat view

Feb 11, 2025

Feb 12 (Reuters) - Supermarket group Ahold Delhaize reported slightly higher-than-expected sales for the fourth quarter on Wednesday, as it saw volume recovery in the U.S. and strong performance in Europe. The Dutch group's revenue for the three months through December 31 was 23.28 billion euros ($24.12 billion), while analysts in a company-compiled poll had estimated it to be 23.21...

China's purchases of chipmaking equipment to decline in 2025, consultancy says

Feb 11, 2025

BEIJING/SHANGHAI (Reuters) - China's purchases of chipmaking equipment are set to decline this year after three years of growth, as the industry grapples with overcapacity and faces greater constraints from U.S. sanctions, a consultancy said on Wednesday. China has been the biggest buyer of wafer fabrication equipment for at least the past two years, purchasing $41 billion worth of tools...